SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 92.3% in October

by · The Cerbat Gem

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 79,800 shares, an increase of 92.3% from the September 30th total of 41,500 shares. Approximately 1.1% of the company’s shares are sold short. Based on an average daily trading volume, of 49,400 shares, the short-interest ratio is currently 1.6 days.

Hedge Funds Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. First PREMIER Bank purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned approximately 0.21% of SAB Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. 7.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on SABS shares. Oppenheimer reiterated an “outperform” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a report on Thursday, September 12th. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a report on Monday, August 12th. Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a report on Monday, September 9th. Finally, Craig Hallum started coverage on shares of SAB Biotherapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $11.00 price objective for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Buy” and a consensus price target of $12.40.

View Our Latest Stock Analysis on SABS

SAB Biotherapeutics Trading Up 3.0 %

Shares of NASDAQ:SABS traded up $0.08 during mid-day trading on Friday, hitting $2.77. 20,531 shares of the company traded hands, compared to its average volume of 26,467. The firm’s 50 day simple moving average is $2.76 and its 200 day simple moving average is $3.07. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.24 and a current ratio of 5.24. SAB Biotherapeutics has a 52-week low of $2.16 and a 52-week high of $10.50.

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.34. The company had revenue of $0.26 million during the quarter. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%. As a group, analysts forecast that SAB Biotherapeutics will post -3.59 EPS for the current year.

About SAB Biotherapeutics

(Get Free Report)

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

See Also